SyntheMed’s Repel-CV will be marketed throughout Canada by Force3 Medicale, a Montreal-based distributor of cardiac surgery products.
The Repel-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the body. Repel-CV represents the first in a series of anti-adhesion products under development that are based on the company’s proprietary polymer technology.
Marc Sportsman, vice president of sales at SyntheMed, said: “We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of Repel-CV.”